Arrowhead Pharmaceuticals Reports $27.8M Revenue for Q2 2025, Achieves Net Income of $22.1M for Nine Months

Arrowhead Pharmaceuticals, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending June 30, 2025. The company generated revenue of $27.8 million for the three months ended June 30, 2025, a notable increase from zero revenue in the same period last year. For the nine months ended June 30, 2025, total revenue reached $573.0 million, a substantial rise from $3.6 million in the prior year. This increase was primarily driven by revenue recognition from collaboration agreements with Sarepta Therapeutics and GlaxoSmithKline (GSK).

In terms of profitability, Arrowhead reported a net loss of $175.2 million for the three months ended June 30, 2025, compared to a loss of $170.8 million in the same period of 2024. However, for the nine months ended June 30, 2025, the company achieved a net income of $22.1 million, a significant turnaround from a net loss of $429.0 million in the prior year. The basic net loss per share for the recent quarter was $(1.26), slightly improved from $(1.38) in the previous year.

Operationally, Arrowhead has made strides in its clinical pipeline, including the initiation of several Phase 1/2 clinical trials and the completion of enrollment in multiple Phase 3 trials. The company triggered a $100 million milestone payment from Sarepta after reaching enrollment targets for the ARO-DM1 study. Additionally, Arrowhead signed an asset purchase agreement with Sanofi for the development of investigational cardiometabolic candidates in Greater China, which is expected to yield further milestone payments.

The company’s total assets increased to $1.38 billion as of June 30, 2025, up from $1.14 billion at the end of the previous fiscal year. This growth was supported by a rise in cash and cash equivalents to $129.8 million, alongside $770.6 million in available-for-sale securities. Arrowhead's total liabilities decreased to $860.8 million from $948.7 million, reflecting a reduction in long-term debt obligations. The company’s employee headcount has also expanded, aligning with its growth strategy and increased research and development activities.

Looking ahead, Arrowhead anticipates continued growth driven by its expanding pipeline and strategic collaborations. The company expects to maintain sufficient liquidity to fund operations through at least the next twelve months, bolstered by recent financing activities and milestone payments. The outlook remains positive as Arrowhead progresses through its clinical trials and prepares for potential product launches.